
Opinion|Videos|January 2, 2025
Recent Updates from SKIPPirr – Strategies for Preventing IRR with IV Amivantamab in Patients with EGFR-mutated NSCLC
Author(s)Sid Devarakonda, MD
A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.
Advertisement
Video content above is prompted by the following:
- Please give an overview of monoclonal antibody infusion-related reactions (IRRs) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).
- Please give an overview of the updated results from the phase 2 SKIPPirr trial, focusing on prevention of IRRs. What are the key takeaways?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















